Reading BMRN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BMRN free→Reading BMRN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BMRN free→QuarterlyIQ Insights · BMRN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 2, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the Company) held its 2026 Annual Meeting of Stockholders (the Annual Meeting). At the Annual Meeting, BioMarin’s stockholders approved an amendment to the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, as amended (the 2017 Plan), to increase the number of shares of BioMarin commo…
Results of Operations and Financial Condition. On May 4, 2026, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its first quarter ended March 31, 2026. The Company’s press release issued on May 4, 2026 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Entry into a Material Definitive Agreement. The information set forth in
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On the Closing Date, in connection with the Merger, the Company entered into a Credit Agreement (the “ Credit Agreement ”), by and among the Company, as borrower, the lenders and issuing banks from time to time party thereto, and Citibank, N.A., as administrative agent and collateral agent (in such capacities, the “ Administrative Agent ” and the “ Collateral Agent ,” respectivel…
by reference. At the effective time of the Merger (the “ Effective Time ”), each share of common stock, par value $0.01 per share, of Amicus (“ Amicus Common Stock ”) issued and outstanding immediately prior to the Effective Time (other than certain excluded shares as described in the Merger Agreement) was automatically cancelled and converted into the right to receive $14.50 in cash, without interest thereon and subject to any applicable withholding of taxes. Pursuant to the Merger Agreement…
Other Events. As previously disclosed, on December 19, 2025, BioMarin Pharmaceutical Inc. (“ BioMarin ”) and Lynx Merger Sub 1, Inc., a wholly owned subsidiary of BioMarin (“ Merger Sub ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Amicus Therapeutics, Inc. (“ Amicus ”), providing for the merger of Merger Sub with and into Amicus (the “ Merger ”), with Amicus surviving the Merger as a wholly owned subsidiary of BioMarin. On April 23, 2026, the Ministry of Eco…
Importance-ranked changes since the prior daily snapshot.
Signal changed from 'mixed' to 'mild_favorable'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.